Medicament (A) comprises 5-methyl-(6S)-tetrahydrofolate, one or more estrogen and/or gestagene, optionally vitamin B6 and/or vitamin B2 and auxiliary or carrier materials. Independent claims are included for: (1) a kit comprising at least 20 daily dose units of (A), at least a daily dose unit containing 5-methyl-(6S)-tetrahydrofolate and optionally vitamin B6 and/or vitamin B2 (where the amount of all the dose units in the kit is at least 28, and the dose unit of (A) is administrated first and subsequently the dose unit containing 5-methyl-(6S)-tetrahydrofolate)； and (2) preparation of the medicament which comprising granulating 5-methyl-(6S)-tetrahydrofolate. ACTIVITY : Cardiant； Uropathic； Cytostatic； Antiinfertility； Tests are described, but no results are given. MECHANISM OF ACTION : None given.本發明係關於一種醫藥組合物，其包含黃體激素(較佳為屈螺酮(drospirenone))、雌激素(較佳為炔雌醇)及5－甲基－(6S)－四氫葉酸鹽，其可用作口服避孕藥，且可防止服用者發生由葉酸鹽缺乏引起之病症，尤其是心血管病症，及胚胎在受孕後由葉酸鹽缺乏引起之先天性畸形，例如神經管缺陷、心室瓣缺陷、泌尿生殖器缺陷及唇裂、頜裂與顎裂，而不會遮蔽維生素B12缺乏之症狀，且同時即使在亞甲基四氫葉酸鹽還原酶之同型接合或異型接合的多型性之情況下，亦可促進人體不會減少葉酸鹽組份5－甲基－(6S)－四氫葉酸鹽利用，且因而促進其防止由葉酸鹽缺乏所引起之上述先天性畸形之生物活性。另外，在停用該避孕藥後仍可維持長時間之保護效應。
